Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Dearnaley

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
Genetic Epidemiology|July 20, 2011
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impactRobert J Macinnis, Antonis C Antoniou, Rosalind A Eeles, et al.
Ebiomedicine|August 13, 2016
Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate CancerSarah L Kerns, Leila Dorling, Laura Fachal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2017
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled TrialMalcolm D Mason, Noel W Clarke, Nicholas D James, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 3, 2014
A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicityGillian C Barnett, Deborah Thompson, Laura Fachal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.
Nature Genetics|September 22, 2009
Multiple loci on 8q24 associated with prostate cancer susceptibilityAli Amin Al Olama, Zsofia Kote-Jarai, Graham G Giles, et al.
Journal of the National Cancer Institute|June 26, 2008
Multiple loci with different cancer specificities within the 8q24 gene desertMaya Ghoussaini, Honglin Song, Thibaud Koessler, et al.
Journal of the National Cancer Institute|May 17, 2019
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer RadiotherapySarah L Kerns, Laura Fachal, Leila Dorling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2023
Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the ProstateSoumyajit Roy, Tahmineh Romero, Jeff M Michalski, et al.
Plos Medicine|June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trialChris C Parker, Nicholas D James, Christopher D Brawley, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
Genetic Epidemiology|July 20, 2011
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impactRobert J Macinnis, Antonis C Antoniou, Rosalind A Eeles, et al.
Ebiomedicine|August 13, 2016
Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate CancerSarah L Kerns, Leila Dorling, Laura Fachal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2017
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled TrialMalcolm D Mason, Noel W Clarke, Nicholas D James, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 3, 2014
A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicityGillian C Barnett, Deborah Thompson, Laura Fachal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.
Nature Genetics|September 22, 2009
Multiple loci on 8q24 associated with prostate cancer susceptibilityAli Amin Al Olama, Zsofia Kote-Jarai, Graham G Giles, et al.
Journal of the National Cancer Institute|June 26, 2008
Multiple loci with different cancer specificities within the 8q24 gene desertMaya Ghoussaini, Honglin Song, Thibaud Koessler, et al.
Journal of the National Cancer Institute|May 17, 2019
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer RadiotherapySarah L Kerns, Laura Fachal, Leila Dorling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2023
Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the ProstateSoumyajit Roy, Tahmineh Romero, Jeff M Michalski, et al.
Plos Medicine|June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trialChris C Parker, Nicholas D James, Christopher D Brawley, et al.
Pageof 15